Given the pivotal role of the androgen receptor (AR) in PCa occurrence and progression, LIMK inhibitors show promise in reducing PCa cell motility, diminishing AR protein stability and transcriptional activity, thereby holding therapeutic potential in PCa treatment (Mardilovich et al., 2015). Here, AR is linked to posterior cortical atrophy.